VISION:
To Prevent and Cure Liver Disease

MISSION:
To advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care.

American Association for the Study of Liver Diseases
2013 Annual Report

AWARD RECIPIENTS:

2013 Research and Career Development Awards ................................................. 2
2013 AASLD Abstract Awards ................................................................................ 5
2013 Distinguished Award Recipients .................................................................. 8
2013 AASLD Emerging Liver Scholar Resident Travel Award Program ............... 10

TRAIN/EDUCATE:

New Developments in Transplant Hepatology Training ...................................... 11
American Board of Internal Medicine (ABIM) ...................................................... 11
The Liver Meeting® .............................................................................................. 11
Special Interest Groups (SIGs) ............................................................................. 14
Single Topic Conferences ................................................................................... 14
Digestive Disease Week ...................................................................................... 15
LiverLearning® ...................................................................................................... 15
AASLD Curriculum & Training (ACT) ................................................................. 15
ACT-on-HCV ......................................................................................................... 15
Collaboration ...................................................................................................... 16
Journals ............................................................................................................... 17
Clinical Practice Guidelines .............................................................................. 17
Online Expert Advice for Clinicians Treating Hepatitis C .................................. 18

EFFECT:

Public Policy ......................................................................................................... 19

FINANCIALS:

Financials ............................................................................................................. 22

GOVERNANCE:

Governing Board ............................................................................................... 24
Past Presidents ................................................................................................. 25
AASLD Staff ....................................................................................................... 26
The AASLD Research, Career Development, and Abstract Awards are the preeminent awards for liver research and advanced hepatology training. In 2013, AASLD and The AASLD Liver Research Fund committed over $2.4 million in funding for awards and fellowships. This level of funding represents the largest single commitment in support of liver research and advanced hepatology training by any professional organization.

AASLD and the AASLD Liver Research Fund are able to provide funding at a critical time in the careers of young investigators and other healthcare providers, which may encourage them to pursue careers in hepatology. We support three types of Awards:

- **Multi-Year Research Awards** in Basic, Clinical, and Translational Research
- **One-Year Career Development Awards** to encourage frontline providers to pursue specialized training in hepatology
- **Abstract Awards** which allow young investigators the opportunity to present their outstanding research to an international audience at The Liver Meeting®

The AASLD awards program has a proven track record of success. Since 2000, AASLD has funded over $32 million in awards.

### AASLD Liver Scholar Award

A three-year basic science award of $225,000 ($75,000/year) that is designed to bridge the gap between completion of research training and attainment status as an independent research scientist and encourage young investigators to pursue a career in liver-related research. The additional research experience provided by this award enables young researchers to successfully compete for research grants from national sources, particularly the National Institutes of Health (NIH).

**Leela L. Paris, PhD**
Indiana University
Indianapolis, IN
**Mentor:** Joseph Tector, PhD
**Research Project:** The study of SRP and ASGR1 in platelet phagocytosis by the porcine liver

**Wei Qiu, PhD**
 Loyola University Chicago
Chicago, IL
**Mentor:** Tarun Patel, PhD
**Research Project:** Repress HCC development by inhibiting FUMA

AASLD gratefully acknowledges funding for the 2013 Liver Scholars from AbbVie, Genentech, Merck, and donors to the New Challenges-New Solutions Campaign and The AASLD Liver Research Fund.

### AASLD/Alpha-1 Foundation Liver Scholar Award

A three-year basic science award of $225,000 ($75,000/year) with a focus on alpha-1-antitrypsin deficiency-associated liver disease.

This award was established in recognition of the 50th anniversary of the discovery of Alpha-1 Antitrypsin Deficiency.

**Andrew Chu, MD**
Children’s Hospital of Pittsburgh of UPMC
Pittsburgh, PA
**Mentor:** David Perlmutter, MD
**Research Project:** Mechanisms of action for autophagy enhancer drugs on alpha-1-antitrypsin deficiency-associated liver disease

AASLD gratefully acknowledges funding for the 2013 AASLD Alpha-1 Liver Scholar Award from Alpha-1 Foundation, and donors to the New Challenges-New Solutions Campaign and The AASLD Liver Research Fund.

### AASLD Career Development in Liver Transplantation

In Memory of the University of Michigan Transplant Team

A two-year award of $90,000 ($45,000/year) designed to foster career development for an individual performing clinical and/or translational research in the field of liver transplantation and who has shown commitment to excellence in the field at an early stage in their career.

This award was established to honor the Transplant Survival Flight Team whose transport crashed over Lake Michigan on June 4, 2007 on the return leg of an organ procurement mission. This award honors those dedicated to life-saving organ transplantation.

**Michael G. Hughes, Jr., MD**
University of Louisville School of Medicine
Louisville, KY
**Mentor:** Craig J. McClain, MD
**Research Project:** Role of Envelope Protein Glycosylation Sites in Hepatitis C Viral Infection of Liver Allografts

AASLD gratefully acknowledges funding for the 2013 Clinical and Translational Research Award from Astellas USA Foundation and donors to the New Challenges-New Solutions Campaign and The AASLD Liver Research Fund.

### AASLD SHEILA SHERLOCK CLINICAL AND TRANSLATIONAL RESEARCH AWARD IN LIVER DISEASES

This two-year clinical research and/or translational research award of $150,000 ($75,000/year) is intended to foster career development for young investigators performing clinical and/or translational research in a liver-related area who have shown commitment to excellence at an early stage in their research study.

This award is named in honor of Dame Sheila Sherlock for her pioneering research and dedication to young research fellows who helped elevate hepatology to the discipline it is today.

**Monika A. Sarkar, MD, MAS**
University of California, San Francisco
San Francisco, CA
**Mentor:** Marion Peters, MD
**Research Project:** Racial/ethnic Differences in Fibrosis Progression in HIV/HCV Coinfected Women

AASLD gratefully acknowledges funding for the 2013 Sheila Sherlock Clinical and Translational Research Award from Genentech and donors to the New Challenges-New Solutions Campaign and The AASLD Liver Research Fund.

### AASLD Clinical and Translational Research Award in Liver Diseases

This two-year clinical research and/or translational research award of $150,000 ($75,000/year) is intended to foster career development for young investigators performing clinical and/or translational research in a liver-related area who have shown commitment to excellence at an early stage in their research study.

**Brittany N. Bohinc, MD**
Duke University
Durham, NC
**Mentors:** Anna Mae Diehl, MD, and Monika A. Sarkar, MD, MAS
**Research Project:** Non-Alcoholic Fatty Liver Disease Is Associated With Systemic and Hepatic Hypothyroidism

AASLD gratefully acknowledges funding for the 2013 Clinical and Translational Research Award from Merck and donors to the New Challenges-New Solutions Campaign and The AASLD Liver Research Fund.
AASLD Advanced/Transplant Hepatology Fellowship
Provides $60,000 in salary and benefit support for gastroenterology (GI) fellows pursuing an additional full-year of training focused on patient care in advanced/transplant hepatology. The intent of the program is to prepare the trainees to be eligible for certification in transplant hepatology by the American Board of Internal Medicine (ABIM) and/or the American Board of Pediatrics (ABP).

Monique L. Choquette, MD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH
MENTOR: John Bucuvalas, MD

Matthew G. Derene, MD
Mayo Clinic in Rochester
Rochester, MN
MENTOR: Kimberly Wat, MD

Chanda K. Ho, MD, MPH
University of California, San Francisco
San Francisco, CA
MENTOR: Norah Terrault, MD, MPH

K. Rajender Reddy, MD
AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES

AASLD NP/PA Clinical Hepatology Fellowship
Provides $78,000 in salary and benefit support for certified and licensed physician assistants (PA) or nurse practitioners (NP) pursuing a full year of training focused on clinical care in hepatology. This award is designed to increase the number of associate practitioners in clinical hepatology; thereby increasing access for liver disease patients to well-trained clinicians.

Danielle E. Cardona, PA-C
The University of North Carolina at Chapel Hill
Chapel Hill, NC
MENTOR: Jama M. Darling, MD

Melissa Ferrari, PA-C
Hospital of the University of Pennsylvania
Philadelphia, PA
MENTOR: Rajender Reddy, MD

Ann E. (Hagan) Burke, CRNP, FNP-BC
Thomas Jefferson University
Philadelphia, PA
MENTOR: Steven K. Herrine, MD

Melissa R. Laycock, APRN, FNP-BC
Kansas University Medical Center
Kansas City, KS
MENTOR: Richard K. Gilroy, MD

Jordan Mayberry, PA-C
UT Southwestern Medical Center
Dallas, TX
MENTOR: William Lee, MD

PSC Partners Seeking a Cure Award
A $3,000 award presented to the investigator presenting the most promising PSC research at The Liver Meeting®. The recipient must be a primary contributor on the project.

James H. Tabibian, MD
Mayo Clinic in Rochester
Rochester, MN
ABSTRACT TITLE: Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis

AASLD gratefully acknowledges funding for the 2013 PSC Partners Seeking a Cure Award from PSC Partners.

A $1,000 award presented for the best abstract submitted to The Liver Meeting® by a fellow.

Alexandra Menchise, MD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH
ABSTRACT TITLE: Heterozygosity for deleterious mutations in Abcb4 is associated with a pro-inflammatory hepatic transcriptome predisposing neonatal mice to cholestatic liver injury

AASLD gratefully acknowledges funding for the 2013 Fellow Research Award is made possible through a grant from the Sun Trust Foundation.

Pediatric Research Award
A $1,000 award presented for the best abstract submitted to The Liver Meeting® by a physician/scientist with a primary appointment affiliation in a department of pediatrics.

Alexander Wree, MD
University of California, San Diego
San Diego, CA
ABSTRACT TITLE: NAFLD inflammasome activation results in hepatocyte pyroptosis, liver inflammation and fibrosis

AASLD gratefully acknowledges funding for the 2013 Pediatric Research Award is made possible through a grant from the Sun Trust Foundation.

Resident Research Award
The purpose of this $1,000 award is to recognize high quality research undertaken by a resident in training.

The recipient must be a primary contributor on the project and committed to a career in liver disease.

Phillip Levine, MD,CM
Scott & White Hospital, Texas A&M
HSC College of Medicine
Temple, TX
ABSTRACT TITLE: The role of stem cell derived microvesicles and microRNAs during alcoholic liver injury

AASLD gratefully acknowledges funding for the 2013 NP/PA Clinical Hepatology Fellowship Program from AbbVie, AbbVax, Akellas USA Foundation, Gilead Sciences, Merck, Janssen Pharmaceutical Companies, Salix Pharmaceuticals, and donors to the New Challenges New Solutions Campaign and The AASLD Liver Research Fund.
Liver Transplant and/or Hepatobiliary Surgery Award

These $1,000 travel awards enable liver transplant and/or hepatobiliary surgery fellows submitting abstracts for The Liver Meeting® to receive travel support.

Christoph Tschuor, MD
University Hospital Zurich
Zurich, Switzerland
ABSTRACT TITLE: Activation of the Constitutive Androstane Receptor (CAR) reverses deficient liver regeneration in the Small-For-Size Syndrome via Foxm1b and mR375/TAP-dependent pathways

Federico Piñero Fernandez Casares, MD
Hospital Universitario Austral
Buenos Aires, Argentina
ABSTRACT TITLE: Risk Factors of Neurologic Events after Liver Transplantation: Towards a Prognostic Risk Score Assessment

Edmund J. Bini Travel Award

These $500 travel awards enable young investigators submitting abstracts for The Liver Meeting® to receive travel support.

Partha Chandra, PhD
Tulane University Health Sciences Center
New Orleans, LA
ABSTRACT TITLE: Persistently Infected Hepatitis C Virus Cell Culture Impairs Type I But Not Type III IFN Signaling

Young Investigator Travel Awards

These $500 travel awards enable young investigators submitting abstracts for The Liver Meeting® to receive travel support.

Hawwa Alao, MD
National Institutes of Health
Bethesda, MD
ABSTRACT TITLE: Global microRNA profiling reveals complex interactions among hepatic microRNA regulation, hepatitis C virus infection and interferon response

Professor Margit Hamosh Travel Award

This $2,500 memorial travel award was established to honor the memory of Dr. Margit Hamosh’s life and legacy. The award is presented to a fellow or junior investigator who submits the most outstanding abstract on hepatoellular carcinoma research for The Liver Meeting®.

Tsunekazu Oikawa, MD, PhD
UNC Lineberger Comprehensive Cancer Center of the University of North Carolina School of Medicine
Chapel Hill, NC
ABSTRACT TITLE: Human Fibroblast Hepatocellular Carcinomas: Evidence for their Derivation from Biliary Tree Stem Cell Subpopulations

2013 Young Investigator Travel Awards Recipients

2013 AASLD Midlevel Professional Awards Recipients

Infection is Associated with an Increase in Circulating microRNA-122

Gene Im, MD
Mount Sinai School of Medicine
New York, NY
ABSTRACT TITLE: Initial Single-Center Experience in the United States with Early Liver Transplantation for Severe Alcoholic Hepatitis

Yoon Seok Roh, DVM, PhD
University of California, San Diego
San Diego, CA
ABSTRACT TITLE: Hepatoocyte-derived microparticles released during apoptosis induce hepatocellular stellate cells activation and migration

Midlevel Professional Awards

These $500 awards are presented for the best abstracts submitted to The Liver Meeting® by an associate member.

Amy Nelson, BSN, RN, ACRN
National Institutes of Allergy and Infectious Diseases/National Institutes of Health
Bethesda, MD
ABSTRACT TITLE: Impact of Pre-existing Mental Health Disorders on Adherence and Sustained Virologic Response with an Interferon-Free Trial of Sofosbuvir and Ribavirin for Chronic Hepatitis C

Laura Wozniak, MD, MS
University of California, Los Angeles
Los Angeles, CA
ABSTRACT TITLE: Complement Binding Donor Specific Antibodies are Associated with Late Graft Dysfunction Following Pediatric Liver Transplantation

AASLD gratefully acknowledges funding for the 2013 Young Investigator Travel Awards through a gift from Ikaria.
AASLD Distinguished Achievement Award

The AASLD Distinguished Achievement Award is given to an individual in honor of his or her sustained scientific contributions to the field of liver disease and the scientific foundations of hepatology. The award honors a sustained contribution rather than a single discovery or major achievement. The awardee need not be a member of AASLD and may be a non-scientist but the contribution should be solidly in the area of liver disease, physiology, anatomy or pathology.

Frederick J. Suchy, MD
University of Colorado School of Medicine
Aurora, CO

Frederick J. Suchy, MD, graduated from the University of Cincinnati College of Medicine in 1974. He completed pediatric residency and fellowship training in pediatric gastroenterology and hepatology at Cincinnati Children’s Hospital Medical Center with Drs. William K. Schubert and William F. Balistreri. He subsequently was Chief of Pediatric Gastroenterology and Hepatology at Yale University (1988-1996) and Chair of Pediatrics at Mount Sinai School of Medicine (1995-2009).

Dr. Suchy has contributed to the AASLD and the hepatology community in many capacities including memberships on the Research Committee, the Education Committee, several Strategic Planning Committees, and search committees for the AASLD executive director and an editor for HEPATOLOGY. He was elected to the AASLD governing board (1999-2004), and served as President in 2003. He has chaired the Scientific Advisory Committee for Pediatric Liver Diseases of the American Liver Foundation, and was the Vice Chair for Scientific Affairs, National Board of Directors, American Liver Foundation (2006-2010).

His main clinical and research interests are in acute liver failure and liver transplantation.

AASLD Distinguished Service Award

The AASLD Distinguished Service Award is given to an individual in honor of his or her sustained service to AASLD or the liver disease community in general. The award recognizes service provided to the community of hepatology researchers and clinicians over an extended period: service that is well above and beyond that provided by many members who serve on the Governing Board and Committees of AASLD. The awardee need not be a member of AASLD.

Dr. Suchy’s research has been funded by the National Institutes of Health for over three decades. The focus of his work has been on the biology and pathobiology of liver transport systems that contribute to bile formation. He has also had a long-standing clinical focus on pediatric liver disease, and in addition to publication of many reviews, case reports, and book chapters, he is an editor of a comprehensive textbook entitled “Liver Disease in Children” which is now in its 4th edition.

Dr. Suchy is currently Chief Research Officer, Director of The Children’s Hospital Colorado Research Institute, Professor of Pediatrics and Associate Dean for Child Health Research, University of Colorado School of Medicine, Aurora, CO.

AASLD Distinguished Clinician Educator/Mentor Award

The Distinguished Clinician Educator/Mentor Award is given in honor of the sustained service of clinicians to AASLD or the liver community in general. The award recognizes the skills of outstanding clinicians and educators who have made momentous contributions to hepatology over an extended period. The awardee need not be a member of AASLD.

Dr. McCullough has received research and achievement awards from the American Diabetes Association, the Cleveland Foundation and the American Liver Foundation, and served as president of the American Association for the Study of Liver Diseases in 2008. Dr. McCullough’s primary research interests include the study of non-alcoholic steatohepatitis and alcoholic steatohepatitis, abnormal energy and protein metabolism in cirrhosis, and nutritional and pharmacologic strategies to address malnutrition in chronic liver disease. He is a leader in research of nonalcoholic fatty liver disease, a disease that affects nearly all fields of clinical medicine and is the most common form of chronic liver disease in the United States.

Arthur J. McCullough, MD
Digestive Disease Institute at the Cleveland Clinic
Cleveland, OH

Arthur J. McCullough, MD, received his MD degree from the State University of New York (SUNY) at Syracuse in 1974. After his internal medicine and chief medical residency at the Cleveland Clinic Medical Center, where he became Division Chief in 1981. In 2006, he took the position of Chairman of the Cleveland Clinic Department of Gastroenterology and Hepatology and Professor of the Lerner College of Medicine of Case Western Reserve and Vice Chairman for research and education for the Digestive Disease Institute. He is currently the director of research for the Digestive Disease Institute at the Cleveland Clinic.

Over his career, Dr. McCullough has received multiple institutional teaching awards, motivated numerous young physicians, and maintained a clinical excellence enthusiastically endorsed by his patients. He has been named one of the Best Doctors in America and one of the top 75 gastroenterologists in the country, co-authored two books on nonalcoholic fatty liver disease and chaired NIH-funded research on fatty liver disease. Dr. McCullough has received research and achievement awards from the American Diabetes Association, the Cleveland Foundation and the American Liver Foundation, and served as president of the American Association for the Study of Liver Diseases in 2008.

Arthur J. McCullough, MD
Digestive Disease Institute at the Cleveland Clinic
Cleveland, OH

Dr. McCullough has received research and achievement awards from the American Diabetes Association, the Cleveland Foundation and the American Liver Foundation, and served as president of the American Association for the Study of Liver Diseases in 2008. Dr. McCullough’s primary research interests include the study of non-alcoholic steatohepatitis and alcoholic steatohepatitis, abnormal energy and protein metabolism in cirrhosis, and nutritional and pharmacologic strategies to address malnutrition in chronic liver disease. He is a leader in research of nonalcoholic fatty liver disease, a disease that affects nearly all fields of clinical medicine and is the most common form of chronic liver disease in the United States.
2013 AASLD Emerging Liver Scholar Resident Travel Award Program

Ahmed Akhter, MD
University of Wisconsin Hospital and Clinics
MENTOR: Adrian Said, MD

Pranab M. Barman, MD
University of Michigan Health System
MENTOR: Grace Su, MD

Jihane N. Benhannou, MD
University of California, Los Angeles
MENTOR: Simon Beaven, MD

Ruchi Bhatia, MA
Saint Louis University Hospital
MENTOR: Brent Teti, MD

Kristin E. Burke, MD
Beth Israel Deaconess Medical Center
MENTOR: Simon Robinson, MD

David T. Chao, MD
University of Pittsburgh Medical Center
MENTOR: Brenda Nguyen, MD

Cynthia E. Chefrane, MD
University of Iowa Hospitals and Clinics
MENTOR: Michael Voigt, MD

Jacqueline J. Choi, MD
University of Illinois at Chicago Medical Center
MENTOR: Grace Guzman, MD

Doan Y. Diao, MD
The University of Texas Southwestern Medical Center
MENTOR: William M. Lee, MD

Nicholas J. Day, MD
University of Michigan
MENTOR: Anna Suk-Fong Lok, MD

Albert Do, MD
Yale-New Haven Hospital
MENTOR: Guadalupe Garcia-Tsao, MD

Mohannad F. Dugum, MD
Cleveland Clinic Foundation
MENTOR: Nizar Zen, MD

Mathis B. Hilscher, MD
Mayo School of Graduate Medical Education
MENTOR: Vijay Shah, MD

Neha R. Jakhete, MD
Johns Hopkins Hospital
MENTOR: Ayman Koteish, MD

Daniel Joyce, MD
Cleveland Clinic
MENTOR: John J. Fung, MD

Rachel Kohn, MD
Massachusetts General Hospital
MENTOR: Parasia A. Vageli, MD

Jeffrey P. LaFond, MD
University of Virginia
MENTOR: Neeraj Shah, MD

Christina C. Lindenmeyer, MD
Thomas Jefferson University Hospital
MENTOR: Jonathan M. Ferrell, MD

Lisa M. McElroy, MD
Northwestern University
MENTOR: Daniela P. Ladner, MD

Adam Mikolajczyk, MD
The University of Chicago
MENTOR: Andrew Aronsohn, MD

John T. Miura, MD
Medical College of Wisconsin
MENTOR: T. Clark Gamblin, MD

Ornai Y. Moutsh, MD
SUM—Upstate Medical University
MENTOR: Victor Arkooma-Sey, MD

Nirah S. Patel, MD
University of California at San Diego Medical Center
MENTOR: Rohit Loomba, MD

Joshua R. Peck, MD
Wanner Medical Center at The Ohio State University
MENTOR: Jim Hanje, MD

Joseph Roberts, MD
University of Colorado Anschutz Medical Campus
MENTOR: Kiran Bambha, MD

Nitzan C. Roth, MD
University of California Los Angeles
MENTOR: Neil Kaplowitz, MD

Suzanne R. Sharpton, MD
University of California San Francisco
MENTOR: Oren Fux, MD

Shazia M. Siddique, MD
Johns Hopkins Hospital
MENTOR: James Hamilton, MD

Antib L. Tierney, MD
Washington University/ Barnes-Jewish Hospital
MENTOR: Kevin Koremire, MD

Nicole M. Welch, MD
University of Chicago
MENTOR: Nancy Reau, MD

Jiu Dong Yang, MD
University of Arkansas for Medical Sciences/Mayo Clinic
MENTOR: Lewis R. Roberts, MD

Elizabeth X. Zheng, MD
Albert Einstein College of Medicine/ Montefiore Medical Center
MENTOR: Allan Wolkoff, MD

2013 Emerging Liver Scholar Resident Travel Award Recipients

Amirah A. Alkhatib, MD
Johns Hopkins Hospital
MENTOR: Ayman Koteish, MD

Dana M. Dugum, MD
Cleveland Clinic
MENTOR: John J. Fung, MD

Michael D. Galante, MD
Massachusetts General Hospital
MENTOR: Parasia A. Vageli, MD

T. Clark Gamblin, MD
University of Chicago
MENTOR: Andrew Aronsohn, MD

Andrew J. Do, MD
University of California at San Diego Medical Center
MENTOR: Roht Loomba, MD

Aaron E. Page, MD
University of North Carolina
MENTOR: William M. Lee, MD

T. Andrew Poobalasingam, MD
University of California San Francisco Medical Center
MENTOR: Charles Long, MD

2013 AASLD 2013 Emerging Liver Scholar Resident Travel Award Program Recipients

TRAIN/EDUCATE

New Developments in Transplant Hepatology Training: Milestones, EPAs and the In-training Examination

2013 marked many important changes in graduate medical education. The Accreditation Council for Graduate Medical Education (ACGME) introduced the next phase of competency-based training for residency and fellowship programs, called the Next Accreditation System (NAS). Of the key NAS performance indicators, much of the current focus is on milestones. AASLD participated in the development of the subspecialty reporting milestones, which are modeled closely on the Internal Medicine reporting milestones. AASLD was a key participant in the development of Entrustable Professional Activities (EPAs) for Gastroenterology training, which includes the necessary development of competency in general hepatology.

American Board of Internal Medicine (ABIM)

AASLD collaborated with ABIM in 2012 to create a three-year competency-based pilot program in gastroenterology-transplant hepatology training. Now in its second year, the pilot program is a qualitative success in the use of competency-based training concepts, while also effectively reducing the length of training required to become a board-certified Transplant Hepatologist.

The Liver Meeting® 2013—Science, Technology and Collaboration

The Liver Meeting® was designed specifically to educate researchers and clinicians on the dynamic changes in the field of hepatology, to connect leading scientists from around the world, and to incorporate technological solutions to enhance the attendee experience.

During our first ever meeting in Washington, DC, more than 8,800 health professionals from 96 countries met to exchange groundbreaking research and progressive clinical treatments in liver disease. In addition to the educational sessions, the exhibit hall provided attendees the opportunity to further their awareness of products and services available to them. More than 1,000 exhibit staff representing 83 companies including industry, publishing, non-profit organizations and more were on hand to interact with attendees.

Expanding on the in-person experience, AASLD offered a meeting app which included all accepted abstracts, ePosters, LiverLearning®, and, for the first time, a livestream webcast of the Hepatitis
Postgraduate Course

The AASLD Postgraduate Course on New Treatments in Liver Disease: A New Era of Diagnostics, Therapeutics and Intervention in Hepatology, Course Directors: Adrian M. Di Bisceglie, MD and Paul Martin, MD highlighted significant issues of liver research facing physicians today. This course provided 3,200 learners with a comprehensive overview of the state-of-the-art advances in the management of chronic liver diseases based on the latest in both basic and clinical research.

Scientific and Educational Activities at The Liver Meeting®

AASLD offers scientific educational activities that are developed by leading hepatologists. Each activity features expert speakers presenting the finest data in the most current and critical topics of liver disease.

More than 3,100 abstracts were submitted. 72% were accepted for oral and poster presentation with 203 receiving recognition as a Poster of Distinction.

Inspired by more than 40 interactive posters sessions, the oral sessions were complemented to present the most up-to-date research available in the field. The oral sessions were complemented by more than 40 interactive posters sessions. AASLD activities meet the increasing demand of hepatology’s growing importance as a medical specialty by providing participants the opportunity to exchange research, discuss outcomes, and interact with colleagues focused on liver and biliary diseases.

Invited Lectures at The Liver Meeting®

The offering of groundbreaking research by top scientists in their specific areas of hepatobiliary research continued to be a priority. The lectures featured:

Global Forum

The global forum focused on the world-wide public health epidemic of liver diseases caused by excessive alcohol use or obesity and the metabolic syndrome. The aim of this program was to develop a discussion on this topic among the five major regions of the world, North America, Europe, Latin America, Asia, and Africa. The discussion addressed the most important public health problems regarding fatty liver diseases in each of these regions.

Hepatitis Debrief

This session provided a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting® 2013. Attendees left this session with practical knowledge of cutting-edge therapies for chronic hepatitis C. Additionally, for the first time, this program was live streamed to allow participation by those who could not attend in person.

Hans Popper Basic Science State-of-the-Art Lecture

In his lecture titled Alpha-1 Antitrypsin Deficiency: Novel Treatment Strategies Fifty Years After Discovery, David Perlmutter, MD, described the history of the disease, what we have learned about its unique clinical sequelae and novel treatment strategies that originated from understanding the unique pathobiology.

This annual lecture recognizes Dr. Popper, the founder of the American Association for the Study of Liver Diseases (AASLD), for his role in the establishment of HEPATOLOGY and his promotion of the intellectual spirit of the Association.

Leon Schiff State-of-the-Art Lecture

HCV Therapeutics in the Post-Interferon Era: More than the Sum of its Parts? delivered by Robert Schooley, MD, discussed the role of innate immune evasion mechanisms of HCV in establishing and maintaining chronic infection in the liver, and identified the potential implications of viral dynamics and replication fidelity as barriers to the pharmacologic cure of HCV infection.

This annual lecture recognizes Dr. Schiff’s work to elevate the study and practice of hepatology to the discipline it is today. A restricted fund has been established to support the lecture in perpetuity and AASLD gratefully acknowledges the National Genetics Institute for their generous support of this program.

Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture

Anthony Atala, MD, delivered his lecture on Regenerative Medicine: New Approaches to Healthcare that described the field of tissue engineering and regenerative medicine, and explained current research and clinical applications in regenerative medicine.

This annual lecture recognizes the pioneering work that Dr. Starzl has done to elevate liver transplantation from an experimental procedure to one that saves thousands of lives annually. A restricted fund has been established to support the lecture in perpetuity and AASLD gratefully acknowledges the donors to this fund, which includes Astellas USA, for their support.

Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture

William Lee, MD, delivered a lecture titled Acetaminophen and the Liver: Poison or Panacea? that focused on possible reasons for this persistent challenge and areas to explore for future remediation of the problem.

The annual presentation of this lecture continues to recognize Dr. Zimmerman’s contributions to the field by providing valuable insights on liver toxicity and injury. A restricted fund has been established to support the lecture in perpetuity and AASLD gratefully acknowledges Eli Lilly and Company for their generous support of this program.

President’s Choice Lecture

The President’s Choice lecture, Random Germline Mutagenesis in the Analysis of Immunity, delivered by Nobel Laureate Bruce Beutler, MD, described how a classical genetic approach can be used to provide a list of the causes of inherited disease and how it has become practical to saturate the genome of the mouse with mutations and assign cause and effect.
Special Interest Groups (SIGs)

Expanding on the existing 12 SIGs, the Governing Board approved the creation of a Clinical Practice SIG in 2013 to address the needs of AASLD members in the clinical community. Their mission is in development with full formation of the group expected by the end of 2014.

At The Liver Meeting® 2013, two of the six programs developed and presented by SIGs were collaborations by multiple SIGs and the Liver Transplantation and Surgery SIG introduced a poster tour mentorship program. There are currently 2,755 SIG members that participate in the following groups:

- Acute on Chronic Liver Failure
  CHAIR: Jasmohan Bajaj, MD
- Cholestatic Liver Disorders
  CHAIR: Saul J. Karpen, MD, PhD
- Hepatitis B
  CHAIR: Brian J. McMahon, MD
- Hepatitis C
  CHAIR: Michael W. Fried, MD
- Hepatobiliary Neoplasia
  CHAIR: Gregory J. Gores, MD
- Hepatotoxicity
  CHAIR: Robert J. Fontana, MD
- Liver Cell Biology in Hepatic Disease
  CHAIR: Mark A. McMillan, PhD
- Liver Fibrosis
  CHAIR: Natalie Torok, MD
- Liver Transplantation and Surgery
  CHAIR: David C. Muljigian, MD
- Pediatric Liver Disorders
  CHAIR: Regina Gonzalez-Peralta, MD
- Portal Hypertension
  CHAIR: Bhashkupare Garcia-Tsao, MD
- Steatohepatitis
  CHAIR: Mark A. McNiven, PhD

Single Topic Conferences

In 2013, three Single Topic Conferences (STC), one Emerging Trends Conference (ETC) and the AASLD/FDA Workshop were conducted.

1. Clinical Research STC: Portal Hypertension and Variceal Hemorrhage
2. Basic Research STC: Portal Hypertension and Vascular Biology of the Liver
3. Hepatitis STC: Hepatitis C Treatment in Special Populations
4. ETC: Reactivation of Hepatitis B
5. AASLD/FDA Workshop: Trial Designs and Endpoints for Liver Disease Secondary to Nonalcoholic Fatty Liver Disease

Attendee evaluations suggested these conferences meet their objectives, provide excellent interactions and produce new research collaborations.

Of special note, the ETC on Reactivation of Hepatitis B was a cross-disciplinary clinical course featuring speakers and panelists from the American Academy of Dermatology (AAD), American Society of Clinical Oncology (ASCO), American College of Rheumatology (ACR), and National Cancer Institute (NCI). Our joint efforts and persistence as an organization in this area was instrumental in the Food and Drug Administration’s (FDA) announcement of the requirement of a Boxed Warning for the anti-cancer immuno-suppressive drugs Arzerra (ofatumumab) and Rituxan (rituximab).

Digestive Disease Week

DDW is sponsored through the partnership of four leading medical societies focused on the digestive system: AASLD, American Gastroenterological Association (AGA), American Society for Gastrointestinal Endoscopy (ASGE), and The Society for Surgery of the Alimentary Tract (SSAT). As a sponsoring society with a strong presence and an excellent liver and biliary tract education program, AASLD’s successful liver-specific sessions include state-of-the-art presentations, clinical symposia, presidential plenaries, research fora, poster presentations, and a Research Highlights session devoted to Hepatology: The Year in Review.

AASLD Curriculum & Training (ACT)

ACT-FIRST

AASLD in collaboration with the American College of Physicians (ACP), Centers for Disease Control (CDC), U.S. Department of Veterans Affairs (VA), and Project ECHO began development of a hepatology curriculum in 2013. The program will provide training (didactic) in Hepatology to front-line providers, with the ultimate goal of improving the care of patients with liver disease. The first two modules being developed are on Hepatitis B and C and will launch at the ACP Annual Meeting.

LiverLearning®

As AASLD’s official eLearning portal, LiverLearning® has continued to grow in both content and reputation. In 2013, AASLD launched the LiverLearning® mobile application for Apple and Android, allowing the user to view all webcasts and ePosters available on the portal in a mobile format. LiverLearning® now has hundreds of hours of webcasts, over 6,000 abstracts, and over 2,300 ePosters.

ACT-on-HCV

This interactive program provides strategies and mentoring for managing HCV and is designed to increase the confidence and competence of healthcare professionals new to providing care for patients with HCV. It includes interactive online CME/CE-certified modules and experiential component which includes logging direct clinical experiences. The five modules were reviewed and monthly webinars with case-based discussions were offered to participants.
Collaboration

To expand our impact on education, research, training and therapy of liver disease AASLD collaborates with related societies and organizations. AASLD actively seeks cooperative ventures with appropriate national, regional and international organizations in order to pursue projects of mutual interest. These interactions are meant to be mutually beneficial and increase our ability to fulfill our vision and mission of treating and curing liver disease.

2013 collaborative efforts included:

- Alpha-1 Foundation
  - AASLD/Alpha-1 Foundation Liver Scholar Award
- American Board of Internal Medicine (ABIM) Competency-based Curriculum
- The Liver Meeting® Competency Workshop
- American College of Gastroenterology (ACG)
  - Practice Guidelines
  - Training Directors Workshop
- American College of Physicians (ACP)
  - Subspecialty Advisory Group on Socioeconomic Affairs
- Council of Subspecialty Societies
  - ACT-First
- American Gastroenterological Association (AGA)
  - Digestive Disease Week
  - Training Directors Workshop
- American Liver Foundation (ALF)
  - Combined awards selection committee
- American Medical Association
  - Physicians Consortium for Practice Improvement (PCPI)
- American Society of Clinical Oncology (ASCO)
  - GI Cancers Symposium, content advisor
- American Society of Gastrointestinal Endoscopy (ASGE)
  - Digestive Disease Week
  - The Liver Meeting®

Journals

**HEPATOLOGY**

The premier publication in the field of liver disease, HEPATOLOGY publishes original, peer-reviewed articles concerning all aspects of liver structure, function, and disease. Each month, the distinguished editorial board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism.

2013 EDITOR: Michael H. Nathanson, MD

**LIVER TRANSPLANTATION**

Since the first application of liver transplantation in a clinical situation was reported more than twenty years ago, there has been a great deal of growth in this field and more is anticipated. This journal delivers current, peer-reviewed articles on surgical techniques, clinical investigations and drug research—the information necessary to keep abreast of this evolving specialty.

2013 EDITORS: John R. Lake, MD
  - John P. Robbins, MD

**CLINICAL LIVER DISEASE (CLD)**

CLD is the latest online learning resource of AASLD. Clinical in focus, CLD blends text, audio, video, webinars, and other interactive content into education interventions launched every two months. These interventions are designed for any physician or healthcare provider caring for a patient with liver disease.

2013 EDITOR: Michael R. Lucey, MD

**PUBLISHED**

- Long-Term Management of the Successful Adult Liver Transplant (in collaboration with the American Society of Transplantation)
- Long Term Medical Management of the Pediatric Patient following Liver Transplantation (in collaboration with the American Society of Transplantation and endorsement by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition)
- Update of Management of Adult Patients with Ascites due to Cirrhosis
- Evaluation of the Adult Patient for Liver Transplantation (in collaboration with the American Society of Transplantation)

**IN DEVELOPMENT**

- Evaluation of the Pediatric Patient for Liver Transplantation (in collaboration with the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the American Society of Transplantation)
- Diagnosis and Management of Hepatic Encephalopathy (in collaboration with the European Association for the Study of Liver)
Online Expert Advice for Clinicians Treating Hepatitis C

AASLD and the Infectious Diseases Society of America (IDSA), in collaboration with the International Antiviral Society-USA (IAS-USA), established the framework and writing panel to offer up-to-date guidance for the treatment of hepatitis C virus (HCV) infection. The initial recommendations were completed following Food and Drug Administration (FDA) approval of two direct-acting antivirals for the treatment of hepatitis C in late 2013. The Recommendations for Testing, Managing, and Treating HCV were published on a new website, www.HCVguidelines.org, in January 2014.

In contrast with traditional Practice Guidelines, this web-based guidance was developed rapidly and will be revised regularly to keep pace with improved diagnostic tools and new drug options as they meet FDA approval. Recent changes in HCV testing guidelines have led to the diagnosis of increasing numbers of patients who were previously unaware of their infection. The guidance provided through www.HCVguidelines.org comes at a critical time as more and more of these patients seek treatment that has the potential to effectively ‘cure’ them. The website is accessible to all practitioners who treat patients with liver disease and provides expert advice about how to best use the next generation of direct-acting antivirals and other treatment options. A panel of 26 hepatologists and infectious diseases specialists and a patient advocate developed the evidence-based, consensus recommendations.

The initial guidance includes:
• HCV Testing and Linkage To Care
• Recommendations for Initial Treatment of HCV Infection in Patients Starting Treatment
• Retreatment in Persons in Whom Prior Therapy Has Failed
• Unique Patient Populations

Additional sections, including Who Should Be Treated and Monitoring Patients on HCV Therapy, will be included in subsequent updates. It is estimated that between 3 and 4 million Americans are infected with HCV and have chronic liver disease as a result. The most recent generation of direct-acting antivirals has the potential to cure most patients with HCV. However, the rapid pace of drug development has left medical providers and insurance companies unsure what the optimal treatments are. The guidance provided through www.HCVguidelines.org will assist clinicians in using these and other treatments in the care of their patients.

Funding for the project is provided by AASLD and IDSA.

EFFECT

The public policy agenda of the American Association for the Study of Liver Diseases (AASLD) in 2013 continued to grow and evolve. AASLD’s growth reflects the growth in the role of the government in the fields of medical practice and medical research. Gone are the days of AASLD members focused on their labs, or teaching or practice solely. AASLD has been a significant and growing participant as key decisions are made at in both the legislative and executive branches of the government.

A number of seminal events in recent years—the passage of the Affordable Care Act and the Budget Control Act, for example—have greatly enhanced the focus on health care issues in Washington, in general. And, as AASLD members know, the impact of liver disease on the health of Americans has never been greater. Fortunately, the quality of treatments has been improving steadily, particularly with regard to viral hepatitis. AASLD’s mission in this area is to ensure that public policies keep pace with the rapid scientific advancements and understanding that is occurring.

RESEARCH

Strong advocacy for increased funding for research is always one of the primary foci of AASLD during Liver Capitol Hill Day (see below), as well as throughout the year. The level of appropriated funds for the National Institutes of Health (NIH), the Department of Veteran Affairs (DVA) and the Agency for Healthcare Research and Quality (AHRQ) research is critically important to AASLD members—and to their patients. 2013 proved to be an incredibly challenging year on the research funding side, as liver research became “collateral damage” in the budget wars that we are afflicting the Congress at the time. As a result of provision in the Budget Control Act of 2012 and Congress’s inability to reach agreement on funding levels, a process known as sequestration took effect which resulted in a 5.1 percent reduction of all domestic discretionary spending on March 1, 2013. Fortunately, after the government shutdown on October 1 was resolved, cooler heads prevailed and in the FY14 appropriations bill fully 2/3 of the reduction was restored.

The goals associated with AASLD’s public policy mission in research are too numerous to detail here. We continue to pursue these, and all of our public policy priorities, in a reasonable and measured way based upon promoting the strongest science we are able to provide.

PATIENT CARE

The Centers for Disease Control and Prevention (CDC) in Atlanta is the home of the Division of Viral Hepatitis. Funding for this important agency—the only element of CDC that currently addresses liver disease in any way—has been consistently inadequate. AASLD has worked with Congress and the administration and continues to seek additional funding to assure that CDC is able to bring its prevention and treatment messages about viral hepatitis to all fifty states. Hepatitis C screening for persons born between 1945 and 1965 is a strong recommendation of the CDC. However, the US Preventive Services Task Force (USPSTF) reviewed the evidence and gave such screening a C rating, which is critical because an A or B rating would mandate that it be considered an “essential health benefit” and would prohibit charging

PATIENT CARE

The Centers for Disease Control and Prevention (CDC) in Atlanta is the home of the Division of Viral Hepatitis. Funding for this important agency—the only element of CDC that currently addresses liver disease in any way—has been consistently inadequate. AASLD has worked with Congress and the administration and continues to seek additional funding to assure that CDC is able to bring its prevention and treatment messages about viral hepatitis to all fifty states. Hepatitis C screening for persons born between 1945 and 1965 is a strong recommendation of the CDC. However, the US Preventive Services Task Force (USPSTF) reviewed the evidence and gave such screening a C rating, which is critical because an A or B rating would mandate that it be considered an “essential health benefit” and would prohibit charging
co-pays to public and private insurance beneficiaries. AASLD, along with our partners in the patient advocacy community, presented reams of evidence to prove the value of the screening. In an almost unprecedented move, USPSTF reversed itself and gave the screening a B rating, greatly enhancing the potential for identifying hepatitis C patients earlier in their disease.

In addition, with the implementation of the Affordable Healthcare Act (ACA) continuing to move ahead, AASLD has increased its involvement substantially in the development of quality measures for physicians treating patients with liver disease. This complex process will have an important and growing role in the future in assuring access to care for patients and adequate reimbursement for providers.

We have also continued to work closely with some of the leading officials at the US Food and Drug Administration to assure that this important regulatory process continues. We have also continued to work closely with some of the leading officials at the US Food and Drug Administration (FDA). In 2014, we plan to build on this effort and focus on identifying new regimens that can be of benefit to AASLD member-physicians, some of their patients, and our partners from patient advocacy groups.

FEDERAL AGENCY DAY

For the last six years, AASLD has undertaken a significant effort to expand its involvement with a broader spectrum of government agencies. Again in 2013, more than a dozen members of the AASLD Governing Board and committee leadership came to Washington DC to conduct meetings throughout the greater Washington DC area.

One team of AASLD leaders went to NIH and met with the leadership of four different institutes which have significant liver research portfolios. The other team of leaders met with officials from the Office of the Assistant Secretary for Health in the Department of Health and Human Services; the Veterans Health Administration in VA; and the Food and Drug Administration (FDA). In 2014, we plan to build on this effort visiting agencies that will be most beneficial to AASLD members and where the greatest opportunities for advancement exist.

Thank you for your support.
100% of your donation is used to support liver research.

WWW.AASLD.ORG/DONATE
## Statement of Activities and Change in Net Assets

### For the Year Ended December 31, 2012

### With Summarized Financial Information For 2011

### Revenue 2012

<table>
<thead>
<tr>
<th>Description</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Meeting</td>
<td>$3,042,586</td>
<td></td>
</tr>
<tr>
<td>Awards &amp; Grants</td>
<td>$2,319,334</td>
<td></td>
</tr>
<tr>
<td>Communications</td>
<td>$529,361</td>
<td></td>
</tr>
<tr>
<td>Meetings &amp; Education</td>
<td>$1,623,790</td>
<td></td>
</tr>
<tr>
<td>Professional Relations</td>
<td>$219,278</td>
<td></td>
</tr>
<tr>
<td>Publications</td>
<td>$1,499,507</td>
<td></td>
</tr>
<tr>
<td>Leadership, IT &amp; F&amp;A</td>
<td>$1,672,856</td>
<td></td>
</tr>
<tr>
<td>Fr/Liver Research Fund</td>
<td>$263,148</td>
<td></td>
</tr>
<tr>
<td>Membership</td>
<td>$901,921</td>
<td></td>
</tr>
</tbody>
</table>

### Expenses 2012

<table>
<thead>
<tr>
<th>Description</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Meeting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Awards &amp; Grants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Communications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meetings &amp; Education</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professional Relations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Publications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leadership, IT &amp; F&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fr/Liver Research Fund</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Membership</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$6,489,934</td>
<td>$7,424,778</td>
</tr>
<tr>
<td>Investments—Reserve and Endowments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investments—Liver Research Fund</td>
<td>$6,701,312</td>
<td>$7,501,377</td>
</tr>
<tr>
<td>Contributions, current portion</td>
<td>$829,405</td>
<td>$1,153,575</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>785,510</td>
<td>610,288</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>212,821</td>
<td>95,913</td>
</tr>
<tr>
<td>Total current assets</td>
<td>39,565,757</td>
<td>35,586,333</td>
</tr>
</tbody>
</table>

### Liabilities and net assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current portion of notes payable</td>
<td>$161,268</td>
<td>$163,346</td>
</tr>
<tr>
<td>Current portion of bonds payable</td>
<td>100,000</td>
<td>100,000</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>1,089,304</td>
<td>1,600,980</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Membership dues</td>
<td>352,040</td>
<td>718,058</td>
</tr>
<tr>
<td>Meeting registrations and exhibits</td>
<td>6,480</td>
<td>31,705</td>
</tr>
<tr>
<td>Grants and awards payable</td>
<td>1,433,045</td>
<td>1,226,657</td>
</tr>
<tr>
<td>Total current liabilities</td>
<td>3,342,168</td>
<td>3,904,726</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-Term Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notes payable, net of current portion</td>
<td>3,425,977</td>
<td>3,605,205</td>
</tr>
<tr>
<td>Bonds payable, net of current portion</td>
<td>3,300,000</td>
<td>3,400,000</td>
</tr>
<tr>
<td>Interest rate swap obligation</td>
<td>2,446,040</td>
<td>2,461,185</td>
</tr>
<tr>
<td>Deferred compensation liability</td>
<td>159,673</td>
<td>103,362</td>
</tr>
<tr>
<td>Total long term liabilities</td>
<td>9,331,655</td>
<td>9,521,782</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>12,673,750</td>
<td>13,454,478</td>
</tr>
</tbody>
</table>

### Net Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Temporarily Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Permanently Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Expenses

<table>
<thead>
<tr>
<th>Description</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual Meeting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professional Relations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Publication Journals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Communications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research and Fellowship Awards</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meetings and Education</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total supporting services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Membership Development and Website</td>
<td>$921,921</td>
<td>$794,913</td>
</tr>
<tr>
<td>Total program services</td>
<td>$10,154,917</td>
<td>$9,637,195</td>
</tr>
</tbody>
</table>

### Other Items

<table>
<thead>
<tr>
<th>Description</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment (loss) income</td>
<td>$3,207,372</td>
<td>$3,773,256</td>
</tr>
<tr>
<td>Unrealized gain (loss) on interest rate swap obligation</td>
<td>$15,144</td>
<td>$15,144</td>
</tr>
<tr>
<td>Change in net assets before other items</td>
<td>$4,297,578</td>
<td>$4,297,578</td>
</tr>
</tbody>
</table>

### Other Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions, net of current portion</td>
<td>$132,235</td>
<td>$652,640</td>
</tr>
<tr>
<td>Deferred financing cost; net of accumulated amortization of $33,396</td>
<td>$111,575</td>
<td>$116,306</td>
</tr>
<tr>
<td>Deferred compensation investments</td>
<td>$109,673</td>
<td>$103,362</td>
</tr>
<tr>
<td>Deposits</td>
<td>83,978</td>
<td>86,673</td>
</tr>
<tr>
<td>Total other assets</td>
<td>397,891</td>
<td>389,398</td>
</tr>
<tr>
<td>Total assets</td>
<td>$440,320,554</td>
<td>$434,670,574</td>
</tr>
</tbody>
</table>
Governing Board

2014 AASLD Governing Board

President
Adrian M. Di Bisceglie, MD, FACP
Saint Louis University
St. Louis, MO

President-Elect
Gyongyi Szabo, MD, PhD
University of Massachusetts
Worcester, MA

Past-President
J. Gregory Fitz, MD
University of Texas Southwestern
Dallas, TX

Secretary
Gary L. Davis, MD
University of Colorado
Aurora, CO

Treasurer
W. Ray Kim, MD
Stanford University
Stanford, CA

Councilors
Keith D. Lindor, MD
Arizona State University
Phoenix, AZ

Anna Suk-Fong Lok, MD
University of Michigan
Ann Arbor, MI

Ronald J. Sokol, MD
University of Colorado
Aurora, CO

Councilors-at-Large
Raymond T. Chung, MD
Massachusetts General Hospital
Boston, MA

Susan Ornoff, MD
Oregon Health and Science University
Portland, OR

K. Rajender Reddy, MD
University of Pennsylvania
Philadelphia, PA

2013 AASLD Governing Board

President
J. Gregory Fitz, MD
University of Texas Southwestern
Dallas, TX

President-Elect
Adrian M. Di Bisceglie, MD, FACP
Saint Louis University
St. Louis, MO

Past-President
J. Gregory Fitz, MD
University of Texas Southwestern
Dallas, TX

Chair
K. Rajender Reddy, MD
University of Pennsylvania
Philadelphia, PA

2013 AASLD Committee Chairs

Annual Meeting Education Committee
Rebecca G. Wells, MD

Basic Research Committee
Mark J. Caiazza, MD

Clinical Research Committee
Marc G. Ghany, MD

Development Committee
W. Ray Kim, MD

Education Oversight Committee
Gary L. Davis, MD

Ethics Committee
Adrian Reuben, MBBS, FRCP, FACG

Federal Agencies Liaison Committee
CHAIR
J. Gregory Fitz, MD

Surgery and Liver Transplantation Committee
CHAIR
Lynt B. Johnson, MD, MBA

Hepatology Associates Committee
CHAIR
Joy A. Peter, RN, BSN

Journals Publication Committee
CHAIR
Theo Heller, MD

Membership & Mentorship Committee
CHAIR
Steven K. Harrine, MD

Nominating Committee
CHAIR
Guadalupe Garcia-Tsao, MD

Practice Guidelines Committee
Jaevert A. Talwalkar, MD, MPH

Program Evaluation Committee
Mary E. Rivella, MD

Public and Clinical Policy Committee
Nancy Reau, MD

Research Awards Committee
Steven Uldahaly, MD, PhD

Research Awards Committee
Linda Greenbaum, MD

Scientific Program Committee
CHAIR
J. Gregory Fitz, MD

Advisory Council

2013 AASLD Past Presidents

2013
J. Gregory Fitz, MD
2012
Guadalupe Garcia-Tsao, MD
2011
T. Jaka Liang, MD
2010
Arun J. Sanjay, MD
2009
Scott L. Friedman, MD
2008
Arthur J. McCullough, MD
2007
Gregory J. Gores, MD
2006
John M. Vielberg, MD, FACP
2005
Teresa L. Wright, MD
2004
Bruce R. Bacon, MD
2003
Frederick J. Suchy, MD
2002
Thomas D. Boyer, MD
2001
Eugene R. Schiff, MD
2000
William F. Balkenreiter, MD
1999
Joseph R. Bloomer, MD
1998
Neil Kaplowitz, MD
1997
Nicholas F. LaRusso, MD
1996
Anthony S. Tavill, MD
1995
D. Montgomery Bissell, MD
1994
John L. Gollan, MD, PhD
1993
Esteban Mazaey, MD
1992
Jay H. Hoofnagle, MD
1991
Michael F. Sorrell, MD
1990
Roger Leaster, MD
1989
Paul D. Bark, MD
1988
David H. Van Thiel, MD
1987
J. Donald Ostrow, MD
1986
Marcus A. Rothschild, MD
1985
Alan F. Holman, MD
1984
Peter R. Thistle, MD
1983
E. Lee Forker, MD
1982
Willy C. Maddrey, MD
1981
Eugene R. Schiff, MD
1980
James L. Boyer, MD
AASLD Staff

Executive Division
Sherrie Cathcart, CAE
Executive Director
Hedi Bruck, MBA
Director, Development
Audrey Davis-Owino
Director, Governance and Practice Guidelines
Kristin Hutcherson
Coordinator, Governance
Julie Merrill
Coordinator, Development
Erica Taylor
Executive Administrative Assistant
Administration and Finance
Nellie Sarkissian
Chief Operations Officer
Mark Islam
Controller
Catherine Celestino
Staff Accountant
Aaron Bats
Junior Accountant

Communications and Public Policy
Gregory Bologna, CAE
Chief Communications Officer
Martha Sauchuk
Director, Marketing
Ann Haran
Senior Manager, Publications
Kristin Howard
Manager, Marketing
Karey Martinez
Manager, Publications
Megan Webster
Coordinator, Marketing
Kara Cheatham
Editorial Assistant, Publications
Tazeen Shroff
Editorial Assistant, Publications

Education and Meetings
Julie Deal
Deputy Executive Director
Janel Klett
Senior Director, Education
Melissa Parrish, CMP
Director, Meetings and Conferences
Denise Seise
Director, Programs and Professional Services
Edward Pramuk
Director, Online Learning
Alena Betar, CMP
Senior Manager, Meetings and Conferences
Allyson Petty
Manager, CME Programs
Anne Wrobel
Manager, CME Programs
Crystal Novas
Coordinator, Meetings and Conferences

IT/Web Services
Paula McGraw
Chief Technology Officer
Chris Dogmore
Director, Data Integrity
Wick Davis
Senior Manager, Website
Roger Rickeli
Manager, Website

Member Services
Bette Anne Preston
Senior Director, Member Services
Mary Kostelc
Manager, Member Services
Erica Lowe
Representative, Member Services